MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway. Read more about MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.
Correction: Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST. Read more about Correction: Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.
A novel isoform of Homeodomain-interacting protein kinase-2 promotes YAP/TEAD transcriptional activity in NSCLC cells. Read more about A novel isoform of Homeodomain-interacting protein kinase-2 promotes YAP/TEAD transcriptional activity in NSCLC cells.
Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Read more about Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002).
Hyperpolarized in vivo pH imaging reveals grade-dependent acidification in prostate cancer. Read more about Hyperpolarized in vivo pH imaging reveals grade-dependent acidification in prostate cancer.
One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer. Read more about One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer.
Correction: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. Read more about Correction: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes.
Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. Read more about Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes.
The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner. Read more about The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner.
Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. Read more about Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001.
